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Summary
The PI3 kinase family of lipid kinases promotes cell growth and survival by generating the second messenger phosphatidy-
linositol-3,4,5-trisphosphate. To define targets critical for cancers driven by activation of PI3 kinase, we screened a panel
of potent and structurally diverse drug-like molecules that target this enzyme family. Surprisingly, a single agent (PI-103)
effected proliferative arrest in glioma cells, despite the ability of many compounds to block PI3 kinase signaling through
its downstream effector, Akt. The unique cellular activity of PI-103 was traced directly to its ability to inhibit both PI3 kinase
a and mTOR. PI-103 showed significant activity in xenografted tumors with no observable toxicity. These data demonstrate
an emergent efficacy due to combinatorial inhibition of mTOR and PI3 kinase a in malignant glioma.Introduction
PI3 kinases are lipid kinases that are activated by a wide range
of receptor tyrosine kinases to generate phosphatidylinositol-
3,4,5-trisphosphate (PIP3). PIP3 couples PI3 kinase to down-
stream effectors such as Akt, a serine-threonine kinase that sig-
nals to suppress apoptosis, promote cell growth, and drive cell
proliferation. PIP3 also indirectly activates the protein kinase
mTOR, which is critical for cell growth and contains a PI3 kinase
homology domain but itself has no lipid kinase activity. The lipid
phosphatase PTEN antagonizes PI3 kinase signaling, as it shows
frequent inactivation in a broad range of tumors (Cantley and
Neel, 1999).
The eight mammalian PI3 kinases are divided into three clas-
ses according to their structure, regulation, and substrate spec-
ificity (Vivanco and Sawyers, 2002). Among these enzymes, the
three class 1A PI3 kinases (p110a, p110b, and p110d) have been
identified as the most critical for cell growth and survivalCANCER CELL 9, 341–349, MAY 2006 ª2006 ELSEVIER INC. DOI 10.10(Vivanco and Sawyers, 2002). Class 1A PI3 kinases are hetero-
dimers of a catalytic p110 lipid kinase subunit and an adaptor
p85 subunit that recruits PI3 kinase to tyrosine phosphorylated
membrane docking sites (Vivanco and Sawyers, 2002). Gain-
of-function mutations in the p110a gene (PIK3CA) are found in
cancers of the colon, breast, and brain (Bachman et al., 2004;
Broderick et al., 2004; Samuels et al., 2004). Nevertheless, the
unique physiological roles of the class 1A isoforms remain
poorly understood, and the biochemical basis for signaling
specificity among these kinases is unknown.
It is increasingly clear that many of the most effective targeted
cancer therapies owe their activity to unexpected synergy
through inhibition of multiple targets. The requirement for inhibi-
tion of multiple targets likely reflects the complexity of signaling
underlying malignant transformation and the ability of tumor
cells to dynamically adapt to stress. For this reason, there is a
growing consensus that inhibition of individual targets is unlikely
to succeed as a therapeutic strategy in solid tumors. Indeed,S I G N I F I C A N C E
PI3 kinases have elicited intense interest as drug targets because primary tumors show frequent inactivation of the tumor suppressor
PTEN (a negative regulator of PI3 kinase) or activatingmutations in PI3 kinasea. Yet it remains unclearwhich kinases in this family should
be targeted in cancer. We report a strategy for pharmacological target validation, based on screening an array of chemically diverse
inhibitors that potently target the PI3 kinase family. We demonstrate that dual blockade of a growth factor-dependent pathway (PI3
kinase) and a nutrient-sensing pathway (mTOR) provides an unusually effective therapeutic window. Moreover, the lead inhibitor
that we report highlights how the conserved nature of the PI3 kinase catalytic domain can be exploited to discover multitargeted
inhibitors with unexpected efficacy.16/j.ccr.2006.03.029 341
A R T I C L Eeven in the simplest hematopoietic malignancies such as
chronic myelogenous leukemia, it has been argued that the effi-
cacy of imatinib requires inhibition of targets other than Bcr-Abl,
the predominant kinase driving this disease (Wong et al., 2004).
Unfortunately, it remains challenging to predict which target
combinations will be most effective in a specific cancer, and ge-
netic inactivation of these targets rarely predicts the efficacy of
the corresponding small molecule drugs (Knight and Shokat,
2005).
As the PI3 kinase family represents an important emerging
class of drug targets, we undertook a pharmacological ap-
proach to define which PI3 kinase family members are critical
for proliferation in malignant glioma. To this end, we have re-
cently synthesized a series of isoform-selective inhibitors of
the PI3 kinase family, defined the structural basis for their spec-
ificity, and systematically enumerated their biochemical targets
relative to all proteins in the family (Knight et al., 2006). These
agents, in conjunction with other recently described isoform-
selective inhibitors of PI3 kinase (Jackson et al., 2005; Knight
et al., 2004; Sadhu et al., 2003), collectively represent, to our
knowledge, the first new tools available in a decade for analysis
of this important signaling pathway. As this inhibitor panel in-
cludes representatives from the majority of chemotypes and
target selectivities currently in preclinical development by the
pharmaceutical industry, it previews the biological activities of
the drugs that will ultimately enter clinical trials. Using this chem-
ical array, we identify a small molecule inhibitor (PI-103) with
unique activity against genetically diverse glioma cell lines.
The activity of this compound was traced to its ability to selec-
tively block p110a and mTOR at nanomolar concentrations.
Combinatorial inhibition of p110a and mTOR was well tolerated
in vivo and was highly effective against glioma xenografts.
These data suggest that combinatorial inhibition of mTOR and
p110a represents a safe and effective therapy in the treatment
of cancers driven by aberrant signaling through PI3 kinase.
Results
Inhibitors of p110a or p110b block activation of the
downstream effector Akt
To understand which PI3 kinase isoforms are critical for the
proliferation of malignant glioma, we evaluated a panel of ten
structurally diverse inhibitors that target these enzymes, recog-
nizing distinct but overlapping target sets (Knight et al., 2006).
For each agent, we screened a panel of six glioma cell lines vary-
ing in mutational status at PTEN or p53 (Table 1; Figure S5 in the
Supplemental Data available with this article online), both of
which are frequently inactivated in gliomas (Rao and James,
2004). This screen demonstrated that inhibitors that target
p110a or p110b were effective in blocking phosphorylation of
Akt (which signals downstream of PI3 kinase), inhibitors selec-
tive for p110d were less active, and none of these compounds
significantly affected signaling through Erk kinase (Figures 1A
and 1B). The p110a inhibitors PI-103 and PIK-90, and the
p110b inhibitor TGX-286, were the most potent of these com-
pounds in blocking phosphorylation of Akt. Although the IC50
measurements of compounds against p110a generally corre-
lated with efficacy against Akt in cells treated in cell culture (Fig-
ures 1A and 1B), this correlation was less precise with inhibitors
of p110b, likely reflecting differences in bioavailability among
these chemotypes.342Selective inhibition of PI3 kinase signaling shows
reduced toxicity in comparison with broad-spectrum
inhibitors
Signaling through PI3 kinase is critical to fundamental pro-
cesses in diverse cell types (Wymann et al., 2003). In part for
this reason, the broad-spectrum PI3-K inhibitors wortmannin
and LY294002 are associated with significant cellular toxicity.
A second potential toxicity relates to inhibition of the PI3 kinase
related kinases ATR, ATM, and DNA-PK, which regulate cell cy-
cle checkpoints and DNA repair. Two lines of investigation were
therefore used to assess potential toxicities of the most active
inhibitor identified in our screen (PI-103).
To address whether PI-103 could induce DNA repair check-
points, leading to an increased mutation rate, we treated glioma
cells with PI-103 and assessed the activation of p53, and of his-
tone gH2AX, which is typically phosphorylated and localized to
nuclear foci in response to DNA damage (Lowndes and Toh,
2005). Neither gH2AX nor p53 was activated by treatment of
glioma cells with PI-103 (Figure S1), suggesting that this com-
pound does not activate DNA damage to an extent measurable
by these assays.
To test whether selective inhibition of p110 isoforms resulted
in decreased cellular toxicity in comparison with broad-
spectrum PI3 kinase inhibitors, we compared PI-103 with
LY294002. U87MG cells were treated with increasing concen-
trations of PI-103 or LY294002 for 24 hr, and the activity of these
inhibitors was measured by monitoring phosphorylation of Akt.
PI-103 inhibited phosphorylation of Akt with an IC95 100-fold
lower than that for LY294002 (Figures 1C and 1D). In parallel ex-
periments, cytoxicity associated with PI-103 or LY294002 was
quantitated by measuring LDH release as an indicator of mem-
brane integrity (Korzeniewski and Callewaert, 1983) and com-
pared with dosages required to block p-Akt. For LY294002,
the IC95 for inhibiting phosphorylation of Akt overlapped with
the cytotoxic dose. In contrast, the IC95 for PI-103 was more
than 10-fold lower than the cytotoxic dose (Figures 1C and
1D). These data indicate that PI-103 can block PI3 kinase signal-
ing at a dose much lower than that which causes general toxic-
ity, suggest that a safe therapeutic index may be possible for
inhibitors of this target class, and validate the approach of
Table 1. Antiproliferative activity of isoform-selective p110 inhibitors
Compound
Most potent isoforms
targeted
Cell cycle distribution
G0G1 S G2M
DMSO — 52 31 17
LY294002 a, b, d, g 59 19 22
Rapamycin mTOR 48 36 16
PIK-90 a 60 31 10
PIK-112 PI-103 inactive analog 55 27 18
PI-103 a 70 22 8
PIK-64 a 53 32 15
PIK-85 a 52 34 13
PIK-93 a 50 36 14
PIK-124 a 53 31 16
TGX-115 b, d 53 32 15
PIK-73 TGX-286 inactive analog 53 31 16
TGX-286 b, d 53 31 16
PIK-108 b, d 53 30 15
PIK-39 d 53 32 15
LN229 glioma cells were treated with isoform-selective inhibitors (0.5 mM),
rapamycin (0.5 nM), or LY294002 (10 mM) for 24 hr and examined by flow
cytometry. Figure S5 shows results for additional glioma cell lines.CANCER CELL MAY 2006
A R T I C L Elinking increased specificity to decreased toxicity within this
class of compounds.
Inhibition of p110a, but not p110b, blocks proliferation
of glioma cells in vitro
Since several chemotypes blocked activation of Akt, we ex-
pected that many compounds would inhibit proliferation in gli-
oma cell lines. Surprisingly, only the p110a inhibitors PI-103,
and to a lesser extent PIK-90, induced proliferative arrest in a
panel of glioma cell lines assayed by flow cytometry (Table 1;
Figure S2). Two lines of evidence suggest that p110a is the
critical target recognized by these inhibitors. First, although
these compounds inhibit p110d and p110g to varying extents
in addition to p110a, Western blot analysis demonstrated no ex-
pression of these isoforms in any of the glioma cell lines tested
(data not shown). It is therefore unlikely that inhibition of p110d
or p110g contributed to the antiproliferative effect of PI-103 or
PIK-90. Second, inhibitors of p110b and p110d (e.g., TGX-286
and PIK-39) had no effect on proliferation of glioma cells
Figure 1. Activity and toxicity of isoform-selective inhibitors of p110 in
comparison with LY294002
All inhibitors were screened against six glioma cell lines.
A and B: Representative results from U373MG cells treated with selective in-
hibitors of p110 catalytic subunits at doses indicated (6 hr). LY294002 served
as positive control, and PIK-112 and PIK73 served as inactive controls. PI-103
showed the highest potency against p-Akt and was therefore further com-
pared with LY294002. None of the compounds tested impacted activation
of Erk kinase in a dose-dependent manner.
C and D: U87MG cells were treated with PI-103 (C) or LY294002 (D) for 24 hr.
Graphs show measurements of cell death by LDH release (three 12-well
plates per experimental point). Immunoblot shows levels of phosphorylated
and total Akt proteins. PI-103 blocked p-Akt at dosages far below the toxic
range, whereas toxic and efficacious dosages for LY294002 were overlap-
ping.CANCER CELL MAY 2006(Table 1), despite the fact that inhibitors selective for p110b
could block phosphorylation of Akt (Figure 1B). Collectively,
these observations suggest that the p110a is functionally the
most important isoform of PI3 kinase for cell growth and trans-
formation in glioma.
Inhibition of p110a cooperates with inhibition of mTOR
in malignant glioma
The increased activity of PI-103 (relative to other p110a inhibi-
tors) in blocking proliferation of glioma cell lines led us to ask
whether the activity of this compound might require inhibition
of other proteins within the PI3 kinase family. In contrast to
PIK-90 and PIK-85, PI-103 does show more potent inhibition
of p110b (Knight et al., 2006). However, addition of a p110b in-
hibitor (TGX115) did not augment the proliferative arrest medi-
ated by the p110a inhibitors PIK-90 or PIK-85 (Table 2). These
data suggest that blockade of p110b does not contribute signif-
icantly to the antiproliferative effects of p110a inhibitors.
In addition to the eight bona fide PI3 kinases, the PI3 kinase
family also includes six protein kinases and two PI4 kinases
(Wymann et al., 2003). We therefore determined the extended
selectivity profile of PI-103 and the other compounds in our
panel by measuring biochemical IC50 values against the remain-
ing proteins in the PI3-K family and 36 protein kinases (Knight
et al., 2006). This analysis revealed that PI-103 uniquely and po-
tently inhibits both complexes of mTOR (Hara et al., 2002; Kim
et al., 2002; Loewith et al., 2002; Zheng et al., 1995): the rapamy-
cin-sensitive mTORC1 (IC50 = 0.02 mM) and the rapamycin-in-
sensitive mTORC2 (IC50 = 0.083 mM). PI-103 inhibited mTOR
in vitro over 50-fold more potently than any other compound in
our panel. While rapamycin is a natural product that only inhibits
mTORC1, PI-103 represents, to our knowledge, the first syn-
thetic compound that potently inhibits both mTOR complexes.
The biochemical activity of this compound against mTOR in vitro
was also observed in cells, where PI-103 (at low nanomolar
doses; IC50 < 0.1 mM) was unique among these compounds in
blocking the phosphorylation of p70 S6 kinase, ribosomal pro-
tein S6, and 4E-BP1, downstream markers of mTOR signaling
(Figure 2A).
As mTOR plays a critical role in controlling cell growth (Aoki
and Vogt, 2004; Inoki et al., 2005), these biochemical data raised
Table 2. Combining inhibitors of PI3 kinase and of mTOR: Effects on
proliferation
Compound
Most potent isoforms
targeted
Cell cycle distribution
G0G1 S G2M
DMSO — 60 28 12
Rapamycin mTOR 77 15 8
PIK-90 a 73 18 9
PIK-90 + rapamycin a + mTOR 85 9 6
PI-85 a 70 22 8
PIK-85 + rapamycin a + mTOR 84 10 6
TGX-115 b 62 26 12
TGX-115 + rapamycin b + mTOR 74 19 7
TGX-286 b 63 26 11
TGX-286 + rapamycin b + mTOR 75 16 9
PIK-90 + TGX-115 a + b 76 15 9
PIK-85 + TGX-115 a + b 71 20 9
U87MG cells were treated for 24 hr with indicated isoform-selective inhibitors
(0.5 mM), rapamycin (0.5 nM), or the combinations shown. Proliferation was
measured by flow cytometry.343
A R T I C L Ethe possibility that cooperative inhibition of p110a and mTOR
may underlie the efficacy of PI-103 in glioma cells. To test this
hypothesis, we asked whether it might be possible to pheno-
copy PI-103 by combining an mTOR inhibitor with an inhibitor
of p110a. PIK-90 inhibits p110a with the same affinity as PI-
103 (IC50 values 8.2 versus 11 nM) and has a similar selectivity
profile against other members of the PI3 kinase family, with
the exception of mTOR. As a single agent, PIK-90 induced
amodest G0G1 arrest (Figure 3A) at a concentration (0.5 mM) suf-
ficient to inhibit phosphorylation of Akt substantially (Figure 3B).
Rapamycin, a widely used allosteric inhibitor of mTORC1 (Hara
et al., 2002; Kim et al., 2002; Loewith et al., 2002; Zheng et al.,
1995), induced a similar partial G0G1 arrest at a concentration
(0.5 nM) sufficient to block phosphorylation of S6 (Figure 3B).
Combining these agents induced a profound cell cycle arrest
that was indistinguishable from PI-103 treatment alone (Fig-
ure 3A). These data argue strongly that the unique cellular activ-
ity of PI-103 is due to cooperative inhibition of two PI3 kinase
family members, p110a and mTORC1.
Interestingly, rapamycin monotherapy activated signaling
through PI3 kinase, presumably due to inhibition of an mTOR-
dependent retrograde signal (Figure 3B). This observation,
which has also beenmade by others (Sun et al., 2005), suggests
that rapamycin blocks one output of Akt signaling (mTOR), at the
expense of activating other outputs. The ability of PI-103 to in-
hibit mTOR, and to block activation of p-Akt in response to
mTOR inhibition, offers a mechanistic rationale for the efficacy
of this combination.
siRNA against p110a blocked phosphorylation of Akt and pro-
liferation, consistent with our findings using small molecule in-
hibitors (Figure S3). Surprisingly, we also observed aproliferative
block using siRNA directed against p110b. As multiple small
molecule inhibitors of p110b blocked phosphorylation of Akt
but had no effect on proliferation either alone or in combination
with inhibitors of mTOR (Table 2), we investigated whether this
discrepancy might reflect differences between how small mole-
cule inhibitors and siRNAs perturb the PI3 kinase pathway.
Figure 2. Activity of isoform-selective inhibitors of p110 against mTOR
A and B: Inhibitors were screened as in Figure 1A. Proteins signaling down-
stream from mTOR include p70 S6 kinase, S6 ribosomal protein, and 4E-BP1.
Each was used to read out mTOR activity. Representative results from
U373MG cells are shown.344Mouse knockout and siRNA studies within the PI3 kinase family
highlight the fact that genetic disruption of the pathway can in-
duce compensatory or unanticipated alterations in the activities
of key regulatory proteins; for this reason, kinase-dead and
kinase-absent mutations often induce different phenotypes (re-
viewed in Hennessy et al., 2005). The p85 regulatory subunits
have been identified as an important component of this com-
pensatory response. Deletion of catalytic p110 subunits has
been shown to affect levels of p85, altering the ratio of p85 to
p110, which controls negative feedback loops within this path-
way (Brachmann et al., 2005). Furthermore, levels of free p85
also impact the activation of regulatory phosphatases (Gupta
et al., 1999) and Jnk (Aguirre et al., 2000; Ueki et al., 2002), which
participate in the complex regulation of PI3 kinase signaling.
Three further experiments were therefore done to clarify the
disparities between small molecule and siRNA experiments di-
rected against p110b. Collectively, these additional experiments
demonstrate that p110a is themajor isoform driving proliferation
in glioma cells.
First, siRNA against p110b led to decreased levels of p85
(Figure S3), consistent with data by others that manipulating
the level of p110b also affects other key regulators of PI3 kinase
signaling (Brachmann et al., 2005), thereby complicating the
interpretation of this experiment.
Second, although the mTOR inhibitor rapamycin cooperated
with small molecule inhibitors of p110a, similar cooperative effi-
cacy was not observed using small molecule inhibitors of p110b
(Figure 3C; Table 2).
Third, in contrast to our studies using small molecule inhibi-
tors of p110a, small molecule inhibitors of p110b failed to block
the activation of PI3 kinase observed in response to inhibition of
mTOR (Figure 3D).
Taken together, these observations argue that p110a is criti-
cal to the proliferation of glioma cells in vitro, that activation of
PI3 kinase in response to mTOR inhibitors is dependent on
p110a to the exclusion of p110b, and that cooperative inhibition
both of p110a and of mTOR underlies the efficacy of PI-103.
PI-103 shows activity in glioma cell lines irrespective of
PTEN, p53, and EGFR status
A number of experiments demonstrate that PI-103 is active in
a broad range of glioma cell lines and that this activity persists
even in the background of mutations, such as PTEN, that acti-
vate signaling through PI3 kinase.
First, the dose response for PI-103 in blocking phosphoryla-
tion of Akt and in inducing proliferative arrest did not change
as a function of PTEN status. We treated U87MG (PTENmutant)
and LN229 (PTENwt) cells with increasing concentrations of PI-
103 and analyzed proliferation, cell cycle distribution, and levels
of phosphorylated Akt by immunoblot (Figure S4). The IC50 for
inhibiting phosphorylation of Akt was between 0.05 and 0.1 mM
(Figures S4A and S4B), consistent with the range of concentra-
tion required to inhibit cell proliferation (Figures S4C and S4D),
and did not differ dramatically between cells wild-type or mutant
at PTEN.
We next tested PI-103 against a larger panel of glioma cell
lines that differed in mutational status of PTEN and p53. Cell
lines were treated with PI-103 (0.5 mM) or LY294002 (10 mM)
and analyzed at 24 hr by immunoblot and flow cytometry. Re-
gardless of PTEN or p53 status, phosphorylation of Akt and
S6 were both decreased in response to PI-103 (Figure S4E).CANCER CELL MAY 2006
A R T I C L EFigure 3. Cooperative inhibition of p110a and
mTOR arrests growth of human glioma cells
U87MG cells were treated with the p110a inhibitor
PIK-90, the p110b inhibitor TGX-286, the mTOR
inhibitor rapamycin, or the dual p110a-mTOR
inhibitor PI-103.
A: Rapamycin cooperated with the p110a inhib-
itor PIK-90 to block proliferation (p < 0.0001 by
Student’s t test for combination therapy at either
concentration, versus rapamycin or versus PIK-90
monotherapy) and was equivalent in efficacy to
PI-103 monotherapy. Error between triplicate
measurements was 0.8% or less for each value
shown.
B:Rapamycin treatment increased phosphoryla-
tion of Akt. Inhibition of mTOR therefore blocked
one output of p-Akt signaling, at the expense of
activating multiple other outputs. Combining in-
hibitors of mTOR with inhibitors of p110a blocks
all p-Akt-driven outputs, offering a mechanistic
rationale for combining inhibitors of mTOR and
of p110a in glioma.
C: In contrast to results combining inhibitors of
p110a with rapamycin, combination therapy
with the p110b inhibitor TGX-286 and rapamycin
failed to potentiate the proliferation block ob-
served with rapamycin alone and was less effec-
tive than PI-103 monotherapy. Error between trip-
licate measurements was 0.9% or less for each
value shown.
D:Cells treated with TGX-286 in combination with
rapamycin showed increased levels of p-Akt,
compared with levels of p-Akt using TGX-286
monotherapy (compare lanes 5–6 with lane 4).
These data, which stand in contrast to those ob-
served using the more effective dual p110a
mTOR inhibitor PI-103 (lane 7), suggest that acti-
vation of PI3 kinase by rapamycin is dependent
on p110a rather than p110band argue that com-
bining inhibitors of mTOR and of p110a will show
efficacy in glioma.PI-103 (0.5 mM) was more active than LY294002 (10 mM) in in-
ducing arrest at G0G1 in all cell lines (Table S1), although one
cell line (LN-Z308) was relatively resistant to both compounds.
Cell cycle arrest induced by PI-103 was not accompanied by
apoptosis in any lines tested, as indicated by measurement
of the sub-G1 fraction TUNEL and cleaved caspase 3 assays
(data not shown). These data demonstrate that PI-103 blocks
proliferation in a broad range of glioma cell lines and argue
that combined inhibition of p110a andmTOR represents a prom-
ising therapeutic strategy in glioma, irrespective of PTEN or p53
status.
Amplification and mutation of EGFR occurs commonly in gli-
oma and is associated with high-grade glioblastoma multiforme
tumors (Agosti et al., 1992; Ekstrand et al., 1992; Schlegel et al.,
1994). Because amplification of EGFR leads to activation of
PI3 kinase, we also tested whether the efficacy of PI-103 was
impacted by activation of EGFR. Since amplification of EGFR
is not maintained in cultured glioma cell lines, we transduced
U8MG human glioma cells with vector, EGFR, or DEGFR—a
tumor-derived allele that signals constitutively in the absence of
ligand (Ekstrand et al., 1992; Wong et al., 1992). Each line was
treated with LY294002 (10 mM) or PI-103 (0.5 mM) in the pres-
ence or absence of EGF (for EGFR-transduced cells). Again,
PI-103wasmore effective than LY294002 in blocking phosphor-
ylation of Akt (Figure 4A) and did not affect phosphorylationCANCER CELL MAY 2006of the receptors. PI-103 paralleled LY294002 in blocking phos-
phorylation of the mTOR target S6 protein in U87MG and
U87MG:DEGFR cells. Neither agent impacted levels of phos-
phorylated S6 in U87MG:EGFR cells. Although wild-type EGFR
differed subtly from DEGFR in response to PI-103, these data
clearly demonstrated equivalent biochemical activity of PI-103
in glioma cell lines with either low or high levels of EGFR.
Inhibition of p110a and of mTOR represents a safe and
effective strategy in EGFR-driven glioma in vivo
We next asked whether PI-103 could be both safe and effective
in treating established U87:DEGFR xenografts in vivo. U87:
DEGFR cells were implanted subcutaneously into nude mice.
When tumors reached 50–100 mm3, animals were randomized
and treated with vehicle or PI-103. PI-103 showed significant
activity in vivo (Figures 4B and 4C), reducing average tumor
size by 4-fold after 18 days (p = 0.0002, Student’s t test). Mice
treated with PI-103 had no obvious signs of toxicity premorbidly
(based on body weight, food andwater intake, activity, and gen-
eral exam) or at necropsy. Treated tumors showed decreased
levels of phosphorylated Akt and S6, consistent with blockade
of p110a and mTOR in vivo (Figure 4D).
To assess whether treatment with PI-103 was cytotoxic or
cytostatic for tumor cells, we treated xenografted animals with
PI-103 or DMSO control and assessed tumors from five mice345
A R T I C L Efor proliferation-BrdU incorporation or apoptosis-caspase 3
activation. Levels of BrdU were decreased in treated tumors
in comparison with control (Figure 4E). Although it has been
Figure 4. Inhibition of p110a and of mTOR represents a safe and effective
strategy in EGFR-driven glioma in vitro and in vivo
A: U87MG, U87MG:DEGFR, and U87MG:EGFR cells were treated with inhibi-
tors shown. EGF (50 ng/ml) was added 30 min prior to harvest, where indi-
cated. Phosphorylation status of EGFR/DEGFR was probed with anti-phos-
photyrosine antibody 4G10. Although U87MG:DEGFR cells show increased
basal activation of both Akt and mTOR signaling in comparison with
U87MG cells, treatment with PI-103 inhibited activation of Akt and of
mTOR pathways in both cell types.
B: U87MG:DEGFR cells were injected subcutaneously in BALB/c nu/nu ani-
mals, five mice in each group, and allowed to establish for 12 days. Animals
were treated with daily PI-103 or DMSO vehicle for 18 days. Each point rep-
resents mean tumor volume 6 SE obtained from five mice.
C: Representative tumors after 18 days of treatment.
D: Immunoblot of tumor lysates demonstrates blockade of p-Akt and p-rpS6
after treatment with PI-103 (T3, T4), compared with control (T1, T2).
E: Five animals treated as in B were injected with BrdU 2 hr prior to sacrifice.
Tumors were analyzed by immunofluorescence with antibody to BrdU (red)
or to cleaved caspase 3 (green) to measure proliferation and apoptosis, re-
spectively. Quantification of five high-power microscopic fields from five an-
imals (in each group) demonstrated a decrease in BrdU levels from 19.1% to
11.4% (p < 0.0001, Student’s t test). Levels of apoptosis were unchanged,
1.2% control versus 1.3% treated (p = 0.13, Student’s t test), suggesting that
PI-103 acts in a tumor-static manner. Panel shows representative images.
Scale bar, 100 mm.346suggested that inhibition of mTORC2 may regulate Akt-depen-
dent survival processes (Guertin and Sabatini, 2005), preclinical
treatment of glioma xenografts with PI-103 (which inhibits
PI3 kinase a, mTORC1, and mTORC2) blocked proliferation
without inducing apoptosis (Figure 4E). These experiments
suggest that PI-103 treatment is cytostatic to glioma xenografts
in vivo.
Discussion
The dramatic clinical efficacy of imatinib combined with the dis-
covery of frequent mutations in protein and lipid kinases that
promote oncogenesis has led to the hope that targeted inhibi-
tion of specific signaling proteins might revolutionize cancer
therapy (Druker, 2004). It is increasingly clear, however, that
many highly selective kinase inhibitors are displaying limited
efficacy in clinical trials, despite the fact that their targets have
been extensively validated to promote tumor progression
(Krause and Van Etten, 2005). Conversely, several of the most
effective kinase inhibitors in clinical development have been
shown to act through complex inhibition of multiple targets
(Fabian et al., 2005). Yet thismultitargeted activity was not inten-
tionally designed into these compounds based on predictive
models of signal transduction.
These observations present a paradox for target-based can-
cer therapy, since this paradigm depends on target validation
prior to compound optimization. We believe that the approach
described in this study illustrates one path toward resolving
this problem, based on the unbiased parallel evaluation of di-
verse chemotypes of potent and selective inhibitors of a single
enzyme family. Through careful correlation of the unique bio-
chemical selectivity profiles of these compounds with their effi-
cacy in cellular and animal model systems, it is possible to phar-
macologically validate specific combinations of targets that are
likely to have efficacy in a particular cancer. In work reported
here, this approach led us to identify a compound that uniquely
inhibits two targets important for glioma proliferation (p110a and
mTOR), despite the fact that many other chemotypes were able
to potently block PI3-K signaling in these cells. Cooperativity be-
tween blockade of PI3 kinase and mTOR signaling also impacts
autophagy in glioma cells (Takeuchi et al., 2005) and may con-
tribute to the efficacy observed in our studies.
The malignant gliomas as a group are rapidly lethal tumors. In
this context, the possibility of later malignancies, secondary to
inhibition of a DNA-PK or other DNA repair checkpoint by PI-
103, presents a relatively minor concern and is not supported
by data included to address this point (Figure S1). As therapy
for these tumors improves, however, it will be important to iden-
tify selective inhibitors of the PI3 kinase family of lipid kinases
that do not inhibit DNA-PK, or other protein kinases critical for
regulation of DNA repair checkpoints. In addition, the family of
PI3 kinase inhibitors could impact such general processes as in-
sulin signaling, diabetes, obesity, and aging. In regards to such
potential toxicities, we believe the key advantage of model com-
pounds such as PI-103 is to identify potential novel target com-
binations that display efficacy in cellular and animal systems.
Actual drugs derived from these lead compounds must then
be evaluated extensively for both efficacy and safety.
Inhibitors of mTOR are currently being tested clinically and
have been somewhat disappointing as monotherapy in cancer.
Although these compounds are cytostatic in many preclinicalCANCER CELL MAY 2006
A R T I C L Estudies (Easton and Houghton, 2004; Takeuchi et al., 2005),
mTOR inhibitors have failed to achieve similar cytostasis in clin-
ical trials (Margolin et al., 2005), suggesting that the utility of
these agents may be improved through combination therapy
(Choo and Blenis, 2006). It has recently been proposed that se-
lective mTOR inhibition may lead to PI3 kinase activation,
thereby limiting the effectiveness of these agents (Hay, 2005).
Our findings in glioma support this model, provide pharmaco-
logical evidence that this feedback can be overcome by dual
inhibition of mTOR and PI3 kinase a, and suggest that inhibition
of PI3 kinase and mTOR in combination should more effectively
achieve cytostasis than inhibition of mTOR alone.
These data support a mechanistic rationale by which inhibi-
tion of a class 1 PI3 kinase can augment the efficacy of mTOR
inhibitors, and in which mTOR inhibition reciprocally augments
the efficacy of class 1 PI3 kinase inhibitors. Activation of
mTOR is influenced by both growth factor- and nutrient-sensing
pathways.While growth factor-sensing pathways signal through
class 1 PI3 kinases, nutrients activate mTOR through a class 3
PI3 kinase (Byfield et al., 2005; Nobukuni et al., 2005). Blockade
of the class 1 PI3 kinase a thus impacts only one of two inputs
driving activation of mTOR. Combining a class 1 PI3 kinase in-
hibitor with an mTOR inhibitor effectively blocks two separate
inputs promoting activation of mTOR, while also preventing
the activation of class 1 PI3 kinases observed in response to
monotherapy with mTOR inhibitors.
In contrast to results using inhibitors of PI3 kinase a, multiple
small molecule inhibitors directed against PI3 kinase b showed
little activity in blocking the proliferation of glioma cells in vitro. In
addition, blockade of PI3 kinase b did not cooperate with block-
ade of mTOR, did not affect the activation of p-Akt observed in
response to inhibiting mTOR, and did not augment the efficacy
of PI3 kinase a inhibitors. These data support the importance of
PI3 kinase a rather than b as the major isoform driving malignant
progression in glioma, a conclusion further supported by siRNA
directed against PI3 kinase a. Interestingly, small molecule and
siRNA approaches were inconsistent regarding a role for PI3 ki-
nase b in this tumor. While we provide a number of experiments
suggesting that the efficacy of siRNAdirected against PI3 kinase
b may be attributable to decreased levels of p85, it is alterna-
tively possible that the biology of perturbations in the PI3 kinase
signaling pathway may differ depending on approach (kinase
knockdown versus kinase inhibition). Our experiments are moti-
vated by translational research and the discovery of small mol-
ecule drug targets for treating human cancers. In this context,
the data presented support further development of PI3 kinase
a-targeting small molecules that also inhibit mTOR and argue
that targeting PI3 kinase b will not be efficacious in this disease
setting.
We have reported here an unbiased screen of diverse small
molecule PI3 kinase inhibitors against malignant glioma. This
screen identified a single agent, PI-103, that induced prolifera-
tive arrest in vitro and inhibited growth of established human tu-
mor xenografts in vivo. Significantly, this high degree of efficacy
was achieved at a low dose of PI-103with no compound-related
side effects. We were able to trace the unique activity of PI-103
to combinatorial inhibition of mTOR and p110a, by showing that
selective inhibitors of mTOR and p110a have limited efficacy in
isolation but phenocopy PI-103 when combined. This suggests
a potentially effective strategy for cancer therapy based on dual
inhibition of these two PI3-K family members.CANCER CELL MAY 2006Experimental procedures
Cell lines, flow cytometry, and cell staining
Human glioma cell lines were obtained from the Brain Tumor Research Cen-
ter at UCSF. Cells were harvested and fixed, treated with RNAase and propi-
dium iodide, and filtered through 95 mM nylon mesh (Small Parts, Inc.). Ten
thousand stained nuclei were analyzed in a FACS Calibur flow cytometer
(Becton Dickinson). DNA histograms were modeled offline using Modifit-LT
software (Verity Software, Topsham,ME). For crystal violet staining, 105 cells
were seeded in 12-well plates in the presence or absence of PI-103.
Immunoblotting, siRNAs, and assessment of cell death
Membranes were blotted with antisera to p-Akt (Ser473), Akt, p-p70 S6
kinase (Thr389), p-70 S6 kinase, p-S6 ribosomal protein (Ser235/236), S6
ribosomal protein, p-4E-BP1 (Thr37/46), p-Erk (Thr202/204), p-p53 (Ser15),
p53, p-gH2A.X (Ser139), H2A.X, and PI3 kinase p110a (all from Cell Signal-
ing); Erk, PI3 kinase p110b, and PI3 kinase p85a (from Santa Cruz); 4G10
and b-tubulin (Upstate Biotechnology); or EGFR/DEGFR (Ab5, NeoMarkers).
Immunoblotting and detection were as previously described (Fan et al.,
2002). siRNA against p110b was from Santa Cruz Biotechnology. Control
siRNA directed against luciferase GL3 (Elbashir et al., 2001) and p110a
siRNA (Czauderna et al., 2003) were fromDharmacon. Cells were transfected
with siRNA using Lipofectamine 2000 (Invitrogen). For assessment of cell
death, U87MG cells were treated with PI-103 or LY294002 for 24 hr. Cell
death was quantified by colorimetric determination of LDH activity using a
cytotoxicity detection kit (Roche). Percentage of cell death (mean of three
12-well plates per experimental point) was calculated [(experimental value2
low control)/(high control 2 low control) 3 100], where the low-control
cells were DMSO treated and high-control cells were Triton treated (1%
Triton X-100, 30 min, 37ºC).
Immunofluorescence
Immunofluorescence staining and visualization of BrdU, cleaved caspase-3,
and p-gH2AX were performed as described previously (Fan et al., 2002).
Sections were incubated overnight at 4ºC with rat monoclonal anti-BrdU
(1:200, Accurate Chemicals) followed by incubation at room temperature
for 1 hr with both anti-rat Alexa Fluor 555 (1:200 Molecular Probes, OR)
and anti-cleaved caspase-3 (Asp175 FITC conjugate, Cell Signaling). For
p-gH2AX staining, cells were permeabilized and incubated with anti-p-
gH2AX (Ser139, Cell Signaling), washed, and incubated for 1 hr in anti-rabbit
Alexa Fluor 555 secondary antibody (Molecular Probes). Nuclei were labeled
with To-Pro-3 iodide (Molecular Probes) for 30 min at RT. Sections and cells
were mounted with Vectashield mounting media (Vector Laboratories) and
analyzed with a Zeiss 510 LSM confocal microscope.
Xenografts
U87MG:DEGFR cells (106) were injected subcutaneously just caudal to the
left forelimb in 6- to 12-week-oldBalbc nu/numice (Harlan Sprague-Dawley).
Mice with established tumors (50–100 mm3) were randomly allocated to IP
treatment with 5 mg/kg PI-103 in 50%DMSO, or 50%DMSO alone (control).
Tumor diameters were measured with calipers at 4 day intervals, and vol-
umes were calculated from five mice per data point (mm3 = width2 3
length/2). At necropsy, gross and microscopic analyses of all organs were
performed to assess toxicity. The UCSF Institutional Animal Care and Use
Committee approved all experiments.
Supplemental data
The Supplemental Data include five supplemental figures and one supple-
mental table and can be found with this article online at http://www.
cancercell.org/cgi/content/full/9/5/341/DC1/.
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